Sarah Henry

Correction: Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study (Cancer Immunology, Immunotherapy, (2023), 72, 2, (475-491), 10.1007/s00262-022-03253-x)

De Jaeghere, EA., Tuyaerts, S., Van Nufel, AMT., Belmans, A., Bogaerts, K., Baiden-Amissah, R., Lippens, L., Vuylsteke, P., Henry, S., Trinh, XB., van Dam, PA., Aspeslagh, S., De Caluwé, A., Naert, E., Lambrechts, D., Hendrix, A., De Wever, O., van de Vijver, KK., Amant, F., Vandecasteele, K., & 1 othersDenys, HG., 30 Dec 2024, In: Cancer Immunology Immunotherapy. 74, 1, 4 p., 32.

Research output: Contribution to journal › Comment/debate